메뉴 건너뛰기




Volumn 32, Issue 29, 2014, Pages 3264-3274

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

(44)  Ustun, Celalettin a   Reiter, Andreas c   Scott, Bart L j   Nakamura, Ryotaro k   Damaj, Gandhi m   Kreil, Sebastian c   Shanley, Ryan a   Hogan, William J b   Perales, Miguel Angel q   Shore, Tsiporah r   Baurmann, Herrad d   Stuart, Robert s   Gruhn, Bernd e   Doubek, Michael t   Hsu, Jack W u   Tholouli, Eleni v   Gromke, Tanja f   Godley, Lucy A w   Pagano, Livio x   Gilman, Andrew z   more..


Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CLINICAL EFFECTIVENESS; DONOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAST CELL LEUKEMIA; MIDDLE AGED; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SYSTEMIC MASTOCYTOSIS; UMBILICAL CORD BLOOD; ADOLESCENT; AGED; ALLOTRANSPLANTATION; CHILD; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MASTOCYTOSIS, SYSTEMIC; MULTICENTER STUDY; PROCEDURES; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84905257818     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.2018     Document Type: Article
Times cited : (145)

References (77)
  • 1
    • 0034983045 scopus 로고    scopus 로고
    • Diagnostic criteria and classification of mastocytosis: A consensus proposal
    • Valent P, Horny HP, Escribano L, et al: Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 25:603-625, 2001
    • (2001) Leuk Res , vol.25 , pp. 603-625
    • Valent, P.1    Horny, H.P.2    Escribano, L.3
  • 2
  • 3
    • 69349102308 scopus 로고    scopus 로고
    • Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients
    • Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, et al: Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 124:514-521, 2009
    • (2009) J Allergy Clin Immunol , vol.124 , pp. 514-521
    • Escribano, L.1    Alvarez-Twose, I.2    Sánchez-Muñoz, L.3
  • 5
    • 84855982233 scopus 로고    scopus 로고
    • Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: A case review
    • Ustun C, Savage NM, Gotlib J, et al: Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: A case review. Am J Hematol 87:191-193, 2012
    • (2012) Am J Hematol , vol.87 , pp. 191-193
    • Ustun, C.1    Savage, N.M.2    Gotlib, J.3
  • 6
    • 67651120132 scopus 로고    scopus 로고
    • Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors
    • Lim KH, Tefferi A, Lasho TL, et al: Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood 113:5727-5736, 2009
    • (2009) Blood , vol.113 , pp. 5727-5736
    • Lim, K.H.1    Tefferi, A.2    Lasho, T.L.3
  • 7
    • 70449706224 scopus 로고    scopus 로고
    • Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
    • Pardanani A, Lim KH, Lasho TL, et al: Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 114:3769-3772, 2009
    • (2009) Blood , vol.114 , pp. 3769-3772
    • Pardanani, A.1    Lim, K.H.2    Lasho, T.L.3
  • 8
    • 78650673033 scopus 로고    scopus 로고
    • How I treat patients with advanced systemic mastocytosis
    • Valent P, Sperr WR, Akin C: How I treat patients with advanced systemic mastocytosis. Blood 116:5812-5817, 2010
    • (2010) Blood , vol.116 , pp. 5812-5817
    • Valent, P.1    Sperr, W.R.2    Akin, C.3
  • 10
    • 0026570013 scopus 로고
    • Response to interferon alfa-2b in a patient with systemic mastocytosis
    • Kluin-Nelemans HC, Jansen JH, Breukelman H, et al: Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 326:619-623, 1992
    • (1992) N Engl J Med , vol.326 , pp. 619-623
    • Kluin-Nelemans, H.C.1    Jansen, J.H.2    Breukelman, H.3
  • 11
    • 12144257058 scopus 로고    scopus 로고
    • Kit as a human oncogenic tyrosine kinase
    • Kitamura Y, Hirotab S: Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61:2924-2931, 2004
    • (2004) Cell Mol Life Sci , vol.61 , pp. 2924-2931
    • Kitamura, Y.1    Hirotab, S.2
  • 12
    • 21344465615 scopus 로고    scopus 로고
    • Clonality and molecular pathogenesis of mastocytosis
    • Akin C: Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 114:61-69, 2005
    • (2005) Acta Haematol , vol.114 , pp. 61-69
    • Akin, C.1
  • 13
    • 0028849992 scopus 로고
    • C-kit point mutation of extracellular domain in patients with myeloproliferative disorders
    • Nakata Y, Kimura A, Katoh O, et al: c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 91:661-663, 1995
    • (1995) Br J Haematol , vol.91 , pp. 661-663
    • Nakata, Y.1    Kimura, A.2    Katoh, O.3
  • 14
    • 33749368009 scopus 로고    scopus 로고
    • KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
    • Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al: KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108:2366-2372, 2006
    • (2006) Blood , vol.108 , pp. 2366-2372
    • Garcia-Montero, A.C.1    Jara-Acevedo, M.2    Teodosio, C.3
  • 15
    • 0028856070 scopus 로고
    • Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
    • Nagata H, Worobec AS, Oh CK, et al: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92:10560-10564, 1995
    • (1995) Proc Natl Acad Sci U S A , vol.92 , pp. 10560-10564
    • Nagata, H.1    Worobec, A.S.2    Oh, C.K.3
  • 16
    • 0009013631 scopus 로고    scopus 로고
    • Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
    • Longley BJ, Tyrrell L, Lu SZ, et al: Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 12:312-314, 1996
    • (1996) Nat Genet , vol.12 , pp. 312-314
    • Longley, B.J.1    Tyrrell, L.2    Lu, S.Z.3
  • 17
    • 13044305857 scopus 로고    scopus 로고
    • Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
    • Longley BJ Jr, Metcalfe DD, Tharp M, et al: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 96:1609-1614, 1999
    • (1999) Proc Natl Acad Sci U S A , vol.96 , pp. 1609-1614
    • Longley, B.J.1    Metcalfe, D.D.2    Tharp, M.3
  • 18
    • 80051475544 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
    • Ustun C, DeRemer DL, Akin C: Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 35:1143-1152, 2011
    • (2011) Leuk Res , vol.35 , pp. 1143-1152
    • Ustun, C.1    DeRemer, D.L.2    Akin, C.3
  • 19
    • 1842579440 scopus 로고    scopus 로고
    • A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib
    • Akin C, Fumo G, Yavuz AS, et al: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103:3222-3225, 2004
    • (2004) Blood , vol.103 , pp. 3222-3225
    • Akin, C.1    Fumo, G.2    Yavuz, A.S.3
  • 20
    • 0041656424 scopus 로고    scopus 로고
    • Imatinib for systemic mast-cell disease
    • Pardanani A, Elliott M, Reeder T, et al: Imatinib for systemic mast-cell disease. Lancet 362:535-536, 2003
    • (2003) Lancet , vol.362 , pp. 535-536
    • Pardanani, A.1    Elliott, M.2    Reeder, T.3
  • 21
    • 54349097778 scopus 로고    scopus 로고
    • Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis
    • Aichberger KJ, Sperr WR, Gleixner KV, et al: Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 38:869-873, 2008
    • (2008) Eur J Clin Invest , vol.38 , pp. 869-873
    • Aichberger, K.J.1    Sperr, W.R.2    Gleixner, K.V.3
  • 22
    • 61449256026 scopus 로고    scopus 로고
    • Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V
    • Ustun C, Corless CL, Savage N, et al: Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 33:735-741, 2009
    • (2009) Leuk Res , vol.33 , pp. 735-741
    • Ustun, C.1    Corless, C.L.2    Savage, N.3
  • 23
    • 52449085884 scopus 로고    scopus 로고
    • Phase II study of dasatinib in Philadelphia chromosomenegative acute and chronic myeloid diseases, including systemic mastocytosis
    • Verstovsek S, Tefferi A, Cortes J, et al: Phase II study of dasatinib in Philadelphia chromosomenegative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3906-3915, 2008
    • (2008) Clin Cancer Res , vol.14 , pp. 3906-3915
    • Verstovsek, S.1    Tefferi, A.2    Cortes, J.3
  • 24
    • 27144506215 scopus 로고    scopus 로고
    • Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
    • Gotlib J, Berubé C, Growney JD, et al: Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106:2865-2870, 2005
    • (2005) Blood , vol.106 , pp. 2865-2870
    • Gotlib, J.1    Berubé, C.2    Growney, J.D.3
  • 25
    • 36349020293 scopus 로고    scopus 로고
    • Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT
    • Gleixner KV, Mayerhofer M, Sonneck K, et al: Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92:1451-1459, 2007
    • (2007) Haematologica , vol.92 , pp. 1451-1459
    • Gleixner, K.V.1    Mayerhofer, M.2    Sonneck, K.3
  • 26
    • 30444446680 scopus 로고    scopus 로고
    • PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: Comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
    • Gleixner KV, Mayerhofer M, Aichberger KJ, et al: PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: Comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107:752-759, 2006
    • (2006) Blood , vol.107 , pp. 752-759
    • Gleixner, K.V.1    Mayerhofer, M.2    Aichberger, K.J.3
  • 27
    • 79952129510 scopus 로고    scopus 로고
    • Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: Myths, controversies, and unknowns
    • Gupta V, Tallman MS, Weisdorf DJ: Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: Myths, controversies, and unknowns. Blood 117:2307-2318, 2011
    • (2011) Blood , vol.117 , pp. 2307-2318
    • Gupta, V.1    Tallman, M.S.2    Weisdorf, D.J.3
  • 28
    • 26444578394 scopus 로고    scopus 로고
    • Myelomastocytic leukemia: Evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation
    • Sperr WR, Drach J, Hauswirth AW, et al: Myelomastocytic leukemia: Evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 11:6787-6792, 2005
    • (2005) Clin Cancer Res , vol.11 , pp. 6787-6792
    • Sperr, W.R.1    Drach, J.2    Hauswirth, A.W.3
  • 29
    • 0028081256 scopus 로고
    • Origin of human mast cells: Development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation
    • Fö dinger M, Fritsch G, Winkler K, et al: Origin of human mast cells: Development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 84:2954-2959, 1994
    • (1994) Blood , vol.84 , pp. 2954-2959
    • Dinger, M.F.1    Fritsch, G.2    Winkler, K.3
  • 30
    • 0031963620 scopus 로고    scopus 로고
    • Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: Review of forty cases
    • Przepiorka D, Giralt S, Khouri I, et al: Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: Review of forty cases. Am J Hematol 57:24-28, 1998
    • (1998) Am J Hematol , vol.57 , pp. 24-28
    • Przepiorka, D.1    Giralt, S.2    Khouri, I.3
  • 31
    • 0037405219 scopus 로고    scopus 로고
    • Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: Analysis of clinicopathologic features and activating c-kit mutations
    • Pullarkat VA, Bueso-Ramos C, Lai R, et al: Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: Analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 73:12-17, 2003
    • (2003) Am J Hematol , vol.73 , pp. 12-17
    • Pullarkat, V.A.1    Bueso-Ramos, C.2    Lai, R.3
  • 32
    • 0026094783 scopus 로고
    • Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome
    • Rønnov-Jessen D, Løvgreen Nielsen P, Horn T: Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 8:413-415, 1991
    • (1991) Bone Marrow Transplant , vol.8 , pp. 413-415
    • Rønnov-Jessen, D.1    Løvgreen Nielsen, P.2    Horn, T.3
  • 33
    • 33845193026 scopus 로고    scopus 로고
    • Neoplastic mast cells in systemic mastocytosis associated with t (8;21) acute myeloid leukemia are derived from the leukemic clone
    • Pullarkat V, Bedell V, Kim Y, et al: Neoplastic mast cells in systemic mastocytosis associated with t (8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 31:261-265, 2007
    • (2007) Leuk Res , vol.31 , pp. 261-265
    • Pullarkat, V.1    Bedell, V.2    Kim, Y.3
  • 34
    • 4644303507 scopus 로고    scopus 로고
    • Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation
    • Spyridonidis A, Thomas AK, Bertz H, et al: Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant 34:515-519, 2004
    • (2004) Bone Marrow Transplant , vol.34 , pp. 515-519
    • Spyridonidis, A.1    Thomas, A.K.2    Bertz, H.3
  • 35
    • 35448970526 scopus 로고    scopus 로고
    • The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia
    • Nagai S, Ichikawa M, Takahashi T, et al: The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Exp Hematol 35:1747-1752, 2007
    • (2007) Exp Hematol , vol.35 , pp. 1747-1752
    • Nagai, S.1    Ichikawa, M.2    Takahashi, T.3
  • 36
    • 0038493777 scopus 로고    scopus 로고
    • Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation
    • Chen TY, Chen JS, Huang WT, et al: Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 32:111-114, 2003
    • (2003) Bone Marrow Transplant , vol.32 , pp. 111-114
    • Chen, T.Y.1    Chen, J.S.2    Huang, W.T.3
  • 37
    • 32844466631 scopus 로고    scopus 로고
    • A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis
    • Nakamura R, Chakrabarti S, Akin C, et al: A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 37:353-358, 2006
    • (2006) Bone Marrow Transplant , vol.37 , pp. 353-358
    • Nakamura, R.1    Chakrabarti, S.2    Akin, C.3
  • 38
    • 84877669323 scopus 로고    scopus 로고
    • Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological nonmast cell lineage disease after allogeneic transplantation
    • Gromke T, Elmaagacli AH, Ditschkowski M, et al: Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological nonmast cell lineage disease after allogeneic transplantation. Bone Marrow Transplant 48:732-733, 2013
    • (2013) Bone Marrow Transplant , vol.48 , pp. 732-733
    • Gromke, T.1    Elmaagacli, A.H.2    Ditschkowski, M.3
  • 40
    • 84866413744 scopus 로고    scopus 로고
    • Death from mast cell leukemia: A young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia
    • Chantorn R, Shwayder T: Death from mast cell leukemia: A young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia. Pediatr Dermatol 29:605-609, 2012
    • (2012) Pediatr Dermatol , vol.29 , pp. 605-609
    • Chantorn, R.1    Shwayder, T.2
  • 41
    • 0345772088 scopus 로고    scopus 로고
    • Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria
    • Valent P, Akin C, Sperr WR, et al: Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria. Leuk Res 27:635-641, 2003
    • (2003) Leuk Res , vol.27 , pp. 635-641
    • Valent, P.1    Akin, C.2    Sperr, W.R.3
  • 42
    • 84878423607 scopus 로고    scopus 로고
    • International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
    • Gotlib J, Pardanani A, Akin C, et al: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 121:2393-2401, 2013
    • (2013) Blood , vol.121 , pp. 2393-2401
    • Gotlib, J.1    Pardanani, A.2    Akin, C.3
  • 43
    • 84872606296 scopus 로고    scopus 로고
    • Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission
    • Oran B, Popat U, Rondon G, et al: Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol Blood Marrow Transplant 19:214-220, 2013
    • (2013) Biol Blood Marrow Transplant , vol.19 , pp. 214-220
    • Oran, B.1    Popat, U.2    Rondon, G.3
  • 44
    • 58149196171 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: Importance of pretransplant disease burden
    • Warlick ED, Cioc A, Defor T, et al: Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: Importance of pretransplant disease burden. Biol Blood Marrow Transplant 15:30-38, 2009
    • (2009) Biol Blood Marrow Transplant , vol.15 , pp. 30-38
    • Warlick, E.D.1    Cioc, A.2    Defor, T.3
  • 45
    • 77956404446 scopus 로고    scopus 로고
    • Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia
    • Gyurkocza B, Storb R, Storer BE, et al: Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 28:2859-2867, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 2859-2867
    • Gyurkocza, B.1    Storb, R.2    Storer, B.E.3
  • 46
    • 10744228781 scopus 로고    scopus 로고
    • Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Disease status by marrow blasts is the strongest prognostic factor
    • Sayer HG, Kröger M, Beyer J, et al: Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31:1089-1095, 2003
    • (2003) Bone Marrow Transplant , vol.31 , pp. 1089-1095
    • Sayer, H.G.1    Kröger, M.2    Beyer, J.3
  • 47
    • 77957278020 scopus 로고    scopus 로고
    • Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure
    • Duval M, Klein JP, He W, et al: Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28:3730-3738, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 3730-3738
    • Duval, M.1    Klein, J.P.2    He, W.3
  • 48
    • 84877684716 scopus 로고    scopus 로고
    • Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia
    • Buckley SA, Appelbaum FR, Walter RB: Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant 48:630-641, 2013
    • (2013) Bone Marrow Transplant , vol.48 , pp. 630-641
    • Buckley, S.A.1    Appelbaum, F.R.2    Walter, R.B.3
  • 49
    • 84887231975 scopus 로고    scopus 로고
    • Achieving stringent CR is essential before reducedintensity conditioning allogeneic hematopoietic cell transplantation in AML
    • Ustun C, Wiseman AC, Defor TE, et al: Achieving stringent CR is essential before reducedintensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant 48:1415-1420, 2013
    • (2013) Bone Marrow Transplant , vol.48 , pp. 1415-1420
    • Ustun, C.1    Wiseman, A.C.2    Defor, T.E.3
  • 50
    • 84055218304 scopus 로고    scopus 로고
    • Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management
    • Estey EH: Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87:89-99, 2012
    • (2012) Am J Hematol , vol.87 , pp. 89-99
    • Estey, E.H.1
  • 51
    • 0037114753 scopus 로고    scopus 로고
    • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461)
    • Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
    • (2002) Blood , vol.100 , pp. 4325-4336
    • Byrd, J.C.1    Mrózek, K.2    Dodge, R.K.3
  • 52
    • 0034672269 scopus 로고    scopus 로고
    • Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study
    • Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000
    • (2000) Blood , vol.96 , pp. 4075-4083
    • Slovak, M.L.1    Kopecky, K.J.2    Cassileth, P.A.3
  • 53
    • 85027957783 scopus 로고    scopus 로고
    • Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chromosomal abnormalities in SM and AHNMD components
    • Wang SA, Hutchinson L, Tang G, et al: Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chromosomal abnormalities in SM and AHNMD components. Am J Hematol 88:219-224, 2013
    • (2013) Am J Hematol , vol.88 , pp. 219-224
    • Wang, S.A.1    Hutchinson, L.2    Tang, G.3
  • 54
    • 84884948790 scopus 로고    scopus 로고
    • Hidden mastocytosis in acute myeloid leukemia with t (8;21) (q22;q22)
    • Johnson RC, Savage NM, Chiang T, et al: Hidden mastocytosis in acute myeloid leukemia with t (8;21) (q22;q22). Am J Clin Pathol 140:525-535, 2013
    • (2013) Am J Clin Pathol , vol.140 , pp. 525-535
    • Johnson, R.C.1    Savage, N.M.2    Chiang, T.3
  • 55
    • 33748467435 scopus 로고    scopus 로고
    • Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t (8; 21): A Cancer and Leukemia Group B Study
    • Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t (8; 21): A Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006
    • (2006) J Clin Oncol , vol.24 , pp. 3904-3911
    • Paschka, P.1    Marcucci, G.2    Ruppert, A.S.3
  • 56
    • 33744487375 scopus 로고    scopus 로고
    • Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
    • Boissel N, Leroy H, Brethon B, et al: Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20:965-970, 2006
    • (2006) Leukemia , vol.20 , pp. 965-970
    • Boissel, N.1    Leroy, H.2    Brethon, B.3
  • 57
    • 80052097088 scopus 로고    scopus 로고
    • Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia
    • Park SH, Chi HS, Min SK, et al: Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 35:1376-1383, 2011
    • (2011) Leuk Res , vol.35 , pp. 1376-1383
    • Park, S.H.1    Chi, H.S.2    Min, S.K.3
  • 58
    • 33646432204 scopus 로고    scopus 로고
    • Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study
    • Cairoli R, Beghini A, Grillo G, et al: Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood 107:3463-3468, 2006
    • (2006) Blood , vol.107 , pp. 3463-3468
    • Cairoli, R.1    Beghini, A.2    Grillo, G.3
  • 59
    • 19944431253 scopus 로고    scopus 로고
    • AML1-ETO and C-KIT mutation/overexpression in t (8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec
    • Wang YY, Zhou GB, Yin T, et al: AML1-ETO and C-KIT mutation/overexpression in t (8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A 102:1104-1109, 2005
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 1104-1109
    • Wang, Y.Y.1    Zhou, G.B.2    Yin, T.3
  • 60
    • 77955275396 scopus 로고    scopus 로고
    • High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V
    • Fritsche-Polanz R, Fritz M, Huber A, et al: High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol 4:335-346, 2010
    • (2010) Mol Oncol , vol.4 , pp. 335-346
    • Fritsche-Polanz, R.1    Fritz, M.2    Huber, A.3
  • 62
    • 31444444950 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity
    • Shimoni A, Hardan I, Shem-Tov N, et al: Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 20:322-328, 2006
    • (2006) Leukemia , vol.20 , pp. 322-328
    • Shimoni, A.1    Hardan, I.2    Shem-Tov, N.3
  • 63
    • 76749091954 scopus 로고    scopus 로고
    • Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia
    • Ringdén O, Labopin M, Ehninger G, et al: Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 27:4570-4577, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 4570-4577
    • Ringdén, O.1    Labopin, M.2    Ehninger, G.3
  • 64
    • 77955886057 scopus 로고    scopus 로고
    • The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission
    • Marks DI, Wang T, Pérez WS, et al: The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 116:366-374, 2010
    • (2010) Blood , vol.116 , pp. 366-374
    • Marks, D.I.1    Wang, T.2    Pérez, W.S.3
  • 65
    • 77951649470 scopus 로고    scopus 로고
    • Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome
    • McClune BL, Weisdorf DJ, Pedersen TL, et al: Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28:1878-1887, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 1878-1887
    • McClune, B.L.1    Weisdorf, D.J.2    Pedersen, T.L.3
  • 66
    • 25144445759 scopus 로고    scopus 로고
    • Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse
    • Sperr WR, Mitterbauer M, Mitterbauer G, et al: Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res 11:6536-6543, 2005
    • (2005) Clin Cancer Res , vol.11 , pp. 6536-6543
    • Sperr, W.R.1    Mitterbauer, M.2    Mitterbauer, G.3
  • 67
    • 70349256069 scopus 로고    scopus 로고
    • Elevated tryptase levels selectively cluster in myeloid neoplasms: A novel diagnostic approach and screen marker in clinical haematology
    • Sperr WR, El-Samahi A, Kundi M, et al: Elevated tryptase levels selectively cluster in myeloid neoplasms: A novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 39:914-923, 2009
    • (2009) Eur J Clin Invest , vol.39 , pp. 914-923
    • Sperr, W.R.1    El-Samahi, A.2    Kundi, M.3
  • 68
    • 0035496941 scopus 로고    scopus 로고
    • Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia
    • Sperr WR, Jordan JH, Baghestanian M, et al: Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 98:2200-2209, 2001
    • (2001) Blood , vol.98 , pp. 2200-2209
    • Sperr, W.R.1    Jordan, J.H.2    Baghestanian, M.3
  • 69
    • 0031760986 scopus 로고    scopus 로고
    • Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells
    • Dimitriadou V, Mécheri S, Koutsilieris M, et al: Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells. J Leukoc Biol 64:791-799, 1998
    • (1998) J Leukoc Biol , vol.64 , pp. 791-799
    • Dimitriadou, V.1    Mécheri, S.2    Koutsilieris, M.3
  • 70
    • 0024439821 scopus 로고
    • Intrathyroidal mast cells express major histocompatibility complex class-II antigens
    • Banovac K, Ghandur-Mnaymneh L, Leone J, et al: Intrathyroidal mast cells express major histocompatibility complex class-II antigens. Int Arch Allergy Appl Immunol 90:43-46, 1989
    • (1989) Int Arch Allergy Appl Immunol , vol.90 , pp. 43-46
    • Banovac, K.1    Ghandur-Mnaymneh, L.2    Leone, J.3
  • 71
    • 0030043421 scopus 로고    scopus 로고
    • Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells
    • Malaviya R, Twesten NJ, Ross EA, et al: Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J Immunol 156:1490-1496, 1996
    • (1996) J Immunol , vol.156 , pp. 1490-1496
    • Malaviya, R.1    Twesten, N.J.2    Ross, E.A.3
  • 72
    • 65249097891 scopus 로고    scopus 로고
    • Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation
    • Kambayashi T, Allenspach EJ, Chang JT, et al: Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation. J Immunol 182:4686-4695, 2009
    • (2009) J Immunol , vol.182 , pp. 4686-4695
    • Kambayashi, T.1    Allenspach, E.J.2    Chang, J.T.3
  • 73
    • 84875524917 scopus 로고    scopus 로고
    • Dissecting graft-versusleukemia from graft-versus-host-disease using novel strategies
    • Warren EH, Deeg HJ: Dissecting graft-versusleukemia from graft-versus-host-disease using novel strategies. Tissue Antigens 81:183-193, 2013
    • (2013) Tissue Antigens , vol.81 , pp. 183-193
    • Warren, E.H.1    Deeg, H.J.2
  • 75
    • 33748320914 scopus 로고    scopus 로고
    • Mast cells are essential intermediaries in regulatory T-cell tolerance
    • Lu LF, Lind EF, Gondek DC, et al: Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442:997-1002, 2006
    • (2006) Nature , vol.442 , pp. 997-1002
    • Lu, L.F.1    Lind, E.F.2    Gondek, D.C.3
  • 77
    • 0037229996 scopus 로고    scopus 로고
    • Recent advances in allogeneic hematopoietic stemcell transplantation
    • Devine SM, Adkins DR, Khoury H, et al: Recent advances in allogeneic hematopoietic stemcell transplantation. J Lab Clin Med 141:7-32, 2003.
    • (2003) J Lab Clin Med , vol.141 , pp. 7-32
    • Devine, S.M.1    Adkins, D.R.2    Khoury, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.